Although some studies have claimed that TFE3-RCC is an inert renal cell carcinoma [11, 12], 38 patients (31.4%) in this Ta cohort had disease progression, and most patients were prone to local recurrence in situ, lung metastasis, and bone metastasis; accordingly, postoperative review is particularly critical. The gene discussed is TFE3; the disease is bone metastasis.